The conversation warns about taking information on pyrilutamide with skepticism, suggesting that many may not have the genuine product. It advises to wait for FDA approval for reliable information.
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
Quitting smoking and vaping, along with taking spirulina, improved hair thickness for some users. Others noted that smoking, vaping, and drinking may contribute to hair thinning.
The conversation humorously discusses hair loss treatments, including finasteride, dutasteride, minoxidil, and microneedling. The user shares progress and thanks the pharmaceutical industry, with comments on the effectiveness and side effects of these treatments.
New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.
Hair loss treatments discussed include Minoxidil, Finasteride, RU58841, and Dutasteride injections. Users believe these treatments are effective and help maintain good hair.
Stem cell and exosome injections for hair loss are discussed, with skepticism about their effectiveness and concerns about using non-genetically related stem cells. Dr. Deyarmin's treatments are mentioned, with some users questioning their legitimacy and others expressing curiosity.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
The user discusses switching from multiple vitamins to a single multivitamin pill. They also mention using oral finasteride and topical minoxidil with finasteride for hair loss treatment.
The conversation is about whether doctors are offering hair transplants using verteporfin. Dr. Bargouthi in Jordan and Dr. Bloxham in New York are currently conducting trials on it.
The user plans to test for DHT, total testosterone, free testosterone, E2, SHBG, and prolactin while supplementing with vitamin D and monitoring ferritin levels. They are experiencing hairline thinning and are seeking advice on whether their approach is excessive or lacking.
A user's 12 month update on treatment for hair loss, which include oral dutasteride and minoxidil, topical RU88541 and minoxidil, microneedling with hyaluronic acid and FinDuta, experiencing no side effects, positive results and inspiring other users.
The user's first hair transplant failed, and they are preparing for a second one. They are considering whether to continue multivitamins and B complex before the surgery, and are asking for advice on supplements to take for hair loss that do not include DHT blockers, finasteride, minoxidil, or high-dose biotin, and are contemplating iron, folic acid, vitamin C, and NAC for before and after the surgery.
The conversation discusses preventing infection from derma stamping for hair loss treatment, with suggestions to reduce needle depth and consider alternatives like tretinoin. The user experienced irritation possibly from zinc chloride and stopped using the shampoo and derma stamping.
The conversation discusses using RU58841, topical finasteride/minoxidil, MK677, and microneedling as treatments for hair loss. MK677 is mentioned as a growth hormone that improves hair health and recovery from microneedling.
A user shared their 9-month post-hair transplant results with 4600 grafts, using only Nourkin hair vitamins, Vitamin D, and B12, and expressed satisfaction. The replies debated the necessity of medications like finasteride and minoxidil for maintaining hair health.
The user experienced hair regrowth using finasteride, minoxidil, biotin, and vitamins, along with exercise and a healthier diet. They reported no side effects from the treatments.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.
User shared 8-month hair loss treatment progress using topical fin/min, topical dut, mk677, RU, and microneedling. They experienced watery semen as a side effect but saw significant improvement in hair growth.
A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.
User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.
Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.
The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.
An 18-year-old experiencing hair loss seeks a finasteride prescription but faces skepticism from doctors who only recommend vitamins. A suggestion is made to consult a dermatologist for a proper diagnosis and potential treatment with finasteride or minoxidil.